Artificial intelligence (AI) and analytics leader SAS, and Thread, have introduced a new offering together to support biopharma companies with data preparation, assessment, and submission.
With the new offering, the companies will be able to modernise their clinical research using a simple and cost-effective method.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
It integrates the comprehensive, cloud-native analytics of SAS with the decentralised clinical trial (DCT) and electronic clinical outcome assessment (eCOA) platform of Thread.
SAS’ Statistical Computing Environment (SCE) solution will initially be integrated with Thread’s technology platform, providing access to data, analysis, and visualisation for shared customers.
This integration will allow SAS and Thread to build on their initial partnership and expand into DCT-specific analytics by combining the data elements, captured by Thread, with SAS AI, visualisation, and machine learning.
Featuring a consolidated analytics environment, the regulatory compliance-enabled solution gathers data from various sources, including participant and clinician-reported data provided by Thread.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition, Thread’s data can be surfaced within customer-specific SAS analytical environments for larger pharmaceutical companies.
Thread co-founder and CEO John Reites said: “To meet the evolving needs of clinical trial participants in the age of digital health, research organisations are transforming the way they discover, develop, manufacture, and commercialise new therapies.
“We are excited to partner with SAS to provide this unique solution to biopharma customers who want to collect data via next-generation research designs.”
In March this year, Thread, along with United BioSource (UBC), launched the next-generation, post-approval research model, SitePlus.
Decentralised Clinical Trial coverage in Clinical Trials Arena is supported by Huma.
Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.
